Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer (ENZAMET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02446405
Recruitment Status : Active, not recruiting
First Posted : May 18, 2015
Last Update Posted : May 3, 2018
Sponsor:
Collaborators:
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
National Health and Medical Research Council, Australia
Cancer Trials Ireland
NCIC Clinical Trials Group
Information provided by (Responsible Party):
University of Sydney

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : September 2020
  Estimated Study Completion Date : December 2020